Fig. 3From: A randomized, double-blind, placebo-controlled 12-week trial of infliximab in patients with juvenile-onset spondyloarthritisMean level of high-sensitive C-reactive protein (hsCRP) and Childhood Health Assessment Questionnaire score (CHAQ) registered during the entire duration of the study (RCT + OLE phases) by treatment group according to randomization. A Mean hsCRP serum levels in milligrammes per decilitre. B Mean CHAQ scores. Lines showed a significant and sustained positive effect of infliximab over timeBack to article page